Fusion Pharmaceuticals Inc. (FUSN)
| Market Cap | 312.85M |
| Revenue (ttm) | 904,000 |
| Net Income (ttm) | -91.99M |
| Shares Out | 63.85M |
| EPS (ttm) | -1.99 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 92,261 |
| Open | 4.97 |
| Previous Close | 5.02 |
| Day's Range | 4.85 - 5.29 |
| 52-Week Range | 1.98 - 5.29 |
| Beta | -1.14 |
| Analysts | Strong Buy |
| Price Target | 9.20 (+87.76%) |
| Earnings Date | May 11, 2023 |
About FUSN
Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to various targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its lead product candidate is FPI-1434 that is in Phase 1 clinical trials as a monotherapy in patients with solid tumors expressing insulin-l... [Read more]
Financial Performance
In 2022, FUSN's revenue was $1.46 million, an increase of 1.46% compared to the previous year's $1.44 million. Losses were -$87.61 million, 8.10% more than in 2021.
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for FUSN stock is "Strong Buy." The 12-month stock price forecast is $9.2, which is an increase of 87.76% from the latest price.
News
Fusion Pharmaceuticals to Present at the Jefferies Healthcare Conference
HAMILTON, ON and BOSTON , May 31, 2023 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as preci...
Fusion Pharmaceuticals Announces First Quarter 2023 Financial Results and Clinical Program Updates
FPI-2265 (Ac-PSMA I&T) program enrolling patients and on track for Q1 2024 update Preliminary Phase 1 data for FPI-1434 expected to be reported at the Society of Nuclear Medicine and Molecular Imagi...
Fusion Pharmaceuticals to Present at the Guggenheim Healthcare Talks Radiopharmaceuticals Day
HAMILTON, ON and BOSTON , May 9, 2023 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precis...
Fusion Pharmaceuticals Announces Opening of Radiopharmaceutical Manufacturing Facility to Produce Targeted Alpha Therapies for Cancer
Facility is on track to be fully operational in 2024 HAMILTON, ON , May 2, 2023 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next...
Fusion Pharmaceuticals to Present at the Bloom Burton & Co. Healthcare Investor Conference
HAMILTON, ON and BOSTON , April 20, 2023 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as pre...
Fusion Pharmaceuticals Announces Presentation of Preclinical Data Supporting FPI-2059 and Leading Targeted Alpha Therapy Platform at AACR Annual Meeting
FPI-2059 induces tumor growth inhibition in colorectal tumor model TEM-1 and EGFRvIII demonstrate potential as TAT targets HAMILTON, ON and BOSTON , April 19, 2023 /PRNewswire/ -- Fusion Pharmaceutica...
Fusion Pharmaceuticals Announces IND Clearance for FPI-2068, a Jointly Developed Novel Targeted Alpha Therapy
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines
Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
HAMILTON, ON and BOSTON, April 5, 2023 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as preci...
Fusion Pharmaceuticals Announces First Patient Dosed in Phase 1 Study of FPI-2059, a Targeted Alpha Therapy (TAT) for the Treatment of Solid Tumors Expressing NTSR1
HAMILTON, ON and BOSTON, March 20, 2023 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as prec...
Fusion Pharmaceuticals Announces Fourth Quarter 2022 Financial Results and Clinical Program Updates
Company recently acquired IND for ongoing Phase 2 clinical trial evaluating 225Ac-PSMA I&T, a small molecule radiopharmaceutical targeting PSMA positive mCRPC FPI-1434 preliminary Phase 1 data expecte...
Fusion Pharmaceuticals to Present at the 43rd Annual Cowen Healthcare Conference
HAMILTON, ON and BOSTON , March 2, 2023 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as prec...
Fusion Pharmaceuticals to Acquire Phase 2 Program for 225Ac-PSMA I&T, a Radiopharmaceutical Targeting Metastatic Castrate Resistant Prostate Cancer
Acquisition of Phase 2 program with established clinical proof of concept strengthens pipeline of innovative targeted alpha therapies In connection with the transaction, Fusion announces $60.0 million...
Fusion Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference
HAMILTON, ON and BOSTON , Feb. 13, 2023 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as prec...
Fusion Pharmaceuticals Reports Progress and Provides Recent Corporate Highlights
FPI-2068 IND expected to be submitted in the first quarter of 2023 FPI-1434 Phase 1 data expected in the second quarter of 2023 FPI-1966 Phase 1 study open and enrolling patients; Company expects to p...
Fusion Pharmaceuticals and BWXT Medical Announce Actinium-225 Partnership to Scale Supply for Developing Targeted Alpha Therapies
- Agreement augments Fusion's existing isotope supply as pipeline of clinical stage actinium-based radiopharmaceuticals grows - Furthers BWXT Medical's position as a global leader in medical isotope...
Fusion Pharmaceuticals Announces Third Quarter 2022 Financial Results and Clinical Program Updates
FPI-1434 Phase 1 data on track to be reported in first half of 2023 Phase 1/2 Study of FPI-1966 open and enrolling patients with solid tumors expressing FGFR3 Strong balance sheet with $205.5 million ...
Fusion Pharmaceuticals Appoints Dmitri Bobilev, M.D. as Chief Medical Officer
HAMILTON, ON and BOSTON, Nov. 7, 2022 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precis...
Fusion Pharmaceuticals to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
HAMILTON, ON and BOSTON , Sept. 7, 2022 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as prec...
Fusion Pharmaceuticals Announces First Patient Dosed in Phase 1/2 Study of FPI-1966 In Patients with Advanced Solid Tumors Expressing FGFR3
HAMILTON, ON and BOSTON , Aug. 29, 2022 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as prec...
Fusion Pharmaceuticals Announces Second Quarter 2022 Financial Results and Clinical Program Updates
FPI-2059 IND cleared by FDA; Clinical portfolio expanded to include small molecule-based targeted alpha therapy Data supporting ongoing evaluation of cold antibody pre-administration dosing regimen in...
Fusion Pharmaceuticals Announces FDA Clearance of IND for FPI-2059, an Investigational Small Molecule-Based Radiopharmaceutical Targeting Solid Tumors Expressing NTSR1
HAMILTON, ON and BOSTON , June 23, 2022 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as prec...
Fusion Pharmaceuticals Presents Imaging Data from Cold Antibody Sub-Study in the Phase 1 Study of FPI-1434
- Study evaluates pre-administration of cold antibody prior to administration of imaging agent - Imaging shows favorable gain in tumor lesion uptake versus normal tissue when cold antibody is pre-admi...
Fusion Pharmaceuticals and Niowave Announce Actinium-225 Collaboration and Supply Agreement
Fusion to invest $5M for guaranteed access to actinium-225 supply Agreement augments Fusion's existing supply as company expands pipeline of actinium-based radio pharmaceuticals HAMILTON, ON and BOSTO...
Fusion's stock falls 4% after announcing two clinical delays
Shares of Fusion Pharmaceuticals Inc. FUSN, -0.54% fell 4.3% in premarket trading on Thursday after the company announced several delays to its oncology program. Fusion said it wouldn't be able to sha...
Fusion Pharmaceuticals Provides Updates on FPI-1434 and FPI-1966 Clinical Programs
HAMILTON, ON and BOSTON , June 9, 2022 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as preci...